ROHIT GOSAIN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ORCHARD PARK, NY NPI 1932515210
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NY Merck Sharp & Dohme Corporation All categories
General Payments — all program years on this page
$7,745.21
- Category: General Payments
- Program years: PY2018–2024
- Record count: 65
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $6,151.93 across 39 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000.00 | 1 |
| Consulting Fee | $1,975.00 | 1 |
| Food and Beverage | $1,089.67 | 33 |
| Travel and Lodging | $1,061.54 | 3 |
| Education | $25.72 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $3,196.05 | 6 |
| EISAI INC. | $2,098.27 | 2 |
| Gilead Sciences, Inc. | $142.32 | 1 |
| E.R. Squibb & Sons, L.L.C. | $138.95 | 4 |
| Janssen Biotech, Inc. | $95.17 | 4 |
| Acerta Pharma LLC | $58.04 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $57.35 | 2 |
| Tempus AI, Inc | $55.28 | 3 |
| PFIZER INC. | $37.00 | 2 |
| Sumitomo Pharma America, Inc. | $32.15 | 2 |
| GENZYME CORPORATION | $30.90 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.99 | 1 |
| Incyte Corporation | $29.18 | 1 |
| Janssen Pharmaceuticals, Inc | $25.72 | 1 |
| Daiichi Sankyo Inc. | $23.69 | 1 |
| Pharmacosmos Therapeutics Inc. | $23.28 | 1 |
| BeiGene USA, Inc. | $21.60 | 1 |
| ADC Therapeutics America, Inc. | $21.11 | 1 |
| GlaxoSmithKline, LLC. | $20.34 | 1 |
| ARRAY BIOPHARMA INC | $15.54 | 1 |
By program year
Records — PY2024 (39)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.